Colcrys — Competitive Intelligence Brief

Colcrys (COLCHICINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkaloid [EPC]. Area: Immunology.

marketed Alkaloid [EPC] Serine/threonine-protein kinase pim-1 Immunology Small molecule

Target snapshot

Colcrys (COLCHICINE) — Scilex Pharms. Colcrys works by inhibiting the activity of a specific enzyme called serine/threonine-protein kinase pim-1.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Colcrys TARGET	COLCHICINE	Scilex Pharms	marketed	Alkaloid [EPC]	Serine/threonine-protein kinase pim-1	1961-01-01
Novantrone	MITOXANTRONE		marketed	Topoisomerase Inhibitor	Serine/threonine-protein kinase pim-1	1987-01-01
Navelbine	vinorelbine	Pierre Fabre	marketed	Vinca Alkaloid	Substance-K receptor	1994-01-01
Oncovin	Vincristine Sulfate	Pfizer Inc.	marketed	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Oncovin	vincristine	Pfizer Inc.	marketed	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Intragastric quinine hydrochloride	Intragastric quinine hydrochloride	Universitaire Ziekenhuizen KU Leuven	marketed	Cinchona alkaloid
Migranal nasal spray at 4 hour	Migranal nasal spray at 4 hour	Thomas Jefferson University	marketed	Ergot alkaloid; 5-HT1B/1D receptor agonist	5-HT1B receptor, 5-HT1D receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkaloid [EPC] class)

1. Scilex Pharms · 1 drug in this class
2. Shanghai Public Health Clinical Center · 1 drug in this class